SCHEMBL4368487

SCHEMBL4368487

NC(=O)c1ccc(F)cc1Cl.O=S(=O)(O)c1ccc(N2CCCC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRK1 P41145 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
JAK2 O60674 2/20 0.41
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA4 P22748 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371350 0.99 KMT2A (0.47) KMT2ASMN1; SMN2OPRM1OPRK1ALDH1A1
SCHEMBL4373567 0.91 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1GAAHSD17B10MAPT
SCHEMBL4374084 0.91 CNR2 (0.43) KMT2AOPRM1OPRK1ALDH1A1GAA
SCHEMBL1887570 0.91 RPS6KB1 (0.45) KMT2ASMN1; SMN2OPRM1OPRK1MAPT
SCHEMBL4370293 0.89 KMT2A (0.47) KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL4370142 0.89 KMT2A (0.45) KMT2AALDH1A1MAPTCA12CA1
SCHEMBL1879254 0.89 KMT2A (0.45) KMT2ASMN1; SMN2ALDH1A1L3MBTL1KDM4E
SCHEMBL1881316 0.89 KDM4E (0.52) KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL4371258 0.88 KMT2A (0.49) KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL4371409 0.88 CA12 (0.43) KMT2ASMN1; SMN2ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625896-B2 Pyridylsulfonamide derivatives HOFFMAN-LA ROCHE INC. (US) 2009-12-01 US claimed
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent HOFFMANN-LA ROCHE INC. 2007-05-31 US claimed
US-7625896-B2 Pyridylsulfonamide derivatives HOFFMAN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent HOFFMANN-LA ROCHE INC. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent TPMT, BPNT1, SLC6A3 KMT2A 959/4885SMN1; SMN2 2452/4885OPRM1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.